QUALIPHAR MEGATONE PLUS Combination Tablet United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

qualiphar megatone plus combination tablet

triangle medical trading l.l.c. belgium - 30's [3x10's blister] - tablet - combination - nutrition , blood-vitamins, nutrition , blood-minerals, nutrition , blood-natural source - see indication field for description

Chlorpromazine Injection BP Kenya - English - Pharmacy and Poisons Board

chlorpromazine injection bp

laborate pharmaceuticals india limited laborate pharmaceuticals india limited e-11 - chlorpromazine injection bp - injection - chlorpromazine hydrochloride bp 25mg - antipsychotics: phenothiazineswith aliphatic

Chlorpromazine Injection BP Kenya - English - Pharmacy and Poisons Board

chlorpromazine injection bp

nestor pharmaceuticals limited po box : 66829-00800 nairobi kenya - chlorpromazine hydrochloride - injection - 25 mg/ ml - antipsychotics: phenothiazineswith aliphatic

DESVENLAFAXINE tablet, extended release United States - English - NLM (National Library of Medicine)

desvenlafaxine tablet, extended release

intellipharmaceutics corp. - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine extended-release tablets, is indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14) ]. •hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. angioedema has been reported in patients treated with desvenlafaxine extended-release tablets [see adverse reactions (6.1) ]. •the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7) and warnings and precautions (5.2) ]. •starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as